JPMorgan analyst Chris Schott upgraded Teva Pharmaceutical to Neutral from Underweight with a $14 price target. Teva continues to progress its innovative pipeline, the analyst tells investors in a research note. The firm says that while it has been concerned the investments required to develop Teva’s assets would pressure margins, the company has done an effective job of partnering programs to address this dynamic. It sees a more balanced risk/reward at current share levels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA: